Table 1. Patients' clinical characteristics.
| Patient ID | Samples1 | Sex | Age at diagnosis (in years) | Site of primary tumor | TNM classification | Site of metastases | Anti-EGFR treatment | Duration of Anti-EGFR Treatment | |
| #1 | PT1, P1_1, P1_2, P1_3 | M | 54 | sigmoid rectum | pTx G2 | biopsy only | liver | Panitumumab (Vectibix) | 23 months |
| #2 | PT2, P2_1, P2_2, P2_3 | M | 72 | sigmoid colon | pT4a N1b (2/14) M1 G2 | resection of primary | liver | Panitumumab (Vectibix) | 6 months |
| #3 | PT3, LM3, P3_1 | F | 70 | transverse colon | pT3 N1 (2/40) M0 G2 | no metastases at time of diagnosis, progression after 9 months | liver, bone, spleen | Cetuximab (Erbitux) | 8 months |
| #4 | PT4, P4_1 | M | 80 | rectum | pT3 N1 M1 G2 | biopsy only | liver (multiple lesions), local recurrence in rectum | Panitumumab (Vectibix) | 8 months |
| #5 | PT5, P5_1 | M | 65 | rectum | pT3 N1 (1/14) M1 G2 | resection of primary | liver | Panitumumab (Vectibix) | 7 months |
| #6 | P6_1, P6_2 | M | 62 | splenic flexture | pT3 N2 (7/13) M1 G2 | resection of primary | liver, peritoneal carcinomatosis, adrenal gland | Cetuximab (Erbitux) | 9 months |
| #7 | P7_1 | M | 81 | splenic flexture | pTx M1 | biopsy only | liver | Cetuximab (Erbitux) and Panitumumab (Vecitibix) | 8 months |
| #8 | M8, P8_1, P8_2 | M | 55 | rectum | pT3 N2 (8/30) M1 G2 L1 | resection of primary | liver | Panitumumab (Vectibix) | 5 months |
| #9 | P9_1 | M | 60 | rectum | pTx G2 | biopsy only | liver | Cetuximab (Erbitux) | 30 months |
| #10 | P10_1, P10_2, P10_3 | F | 65 | sigmoid colon | pT3 N2 (4/30) M0 G2 | no metastases at time of diagnosis, progression after 3 years | lymph nodes intraabdominal | Panitumumab (Vectibix) | 6 months |
1
Sample names starting with “PT” indicate those derived from primary tumors, with “M” from a metastatic lesion, “LM” from a liver metastasis, and “P” indicates the plasma samples.